Tech Company Financing Transactions
Hepta Bio Funding Round
On 11/5/2025, Hepta Bio received $6.7 million in Seed funding from Felicis Ventures, Illumina Ventures and Alumni Ventures.
Transaction Overview
Company Name
Announced On
11/5/2025
Transaction Type
Venture Equity
Amount
$6,700,000
Round
Seed
Investors
Felicis Ventures (Lead Investor) (Aydin Senkut)
Illumina Ventures (Lead Investor)
Proceeds Purpose
The funding will accelerate dataset expansion, platform scaling, regulatory milestones and commercialization to bring Hepta's assay to clinical use.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
A blood-based window on tissue biology supports early detection, treatment decisions, and longitudinal monitoring. Hepta reads molecular signals of liver inflammation and fibrosis from blood with its liquid biopsy-native AI. The same architecture is designed to help clinicians identify patients earlier, match biology to therapy, and follow molecular change over time. We are focused first on MASH. As evidence grows, the platform is designed to extend to other serious chronic diseases driven by similar biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hamed Amini
Browse more venture capital transactions:
Prev: 11/5/2025: Cactus venture capital transaction
Next: 11/5/2025: CeresAI venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs